Objective:To compare and analyze the efficacy and safety of the combination therapy of cetuximab with FOLFOXIRI(irinotecan,oxaliplatin,folic acid,5-FU)versus FOLFOXIRI alone in treating patients with advanced colorectal cancer.Methods:Eighty-six patients were randomly assigned to either the combined treatment group(n=50)or the single treatment group(n=36).The single treatment group received only FOLFOXIRI chemotherapy before radical surgery,while the combined treatment group received FOLFOXIRI therapy combined with cetuximab.Chemotherapy-related indicators,drug adverse reactions,as well as 1-,2-,and 3-year disease-free survival(DFS)and overall survival(OS)rates were compared between the two groups using Kaplan-Meier analysis.Results:The incidence rates of tumor regression grade(TRG)downgrading,T stage downgrading,and N stage downgrading in the combined treatment group were all significantly better than those in the single treatment group(P＜0.05).Adverse reactions including leukopenia,diarrhea,liver and kidney function damage,neurological toxicity,oral mucosal inflammation showed no statistically significant differences between groups(P＞0.05).The 1-,2-,and 3-year DFS rates for both groups were respectively;66.1％,15.3％,11.4％vs.79.2％,49.7％,28.1％.Differences at year-2 & year-3 DFS were statistically significant(P=0.021,P=0..036),while OS at year-2 and year-3 were found to be significantly different(P=0.031).Conclusion:Compared to sole FOLFOXIRI chemotherapy regimen,the combination of cetuximab with FOLFOXIRI regimen for advanced colorectal cancer patients demonstrated notable advantages in tumor downstaging,promoting patient survival without a marked increase in adverse effects or complications,and had a substantial impact on improving overall survival time.
万方数据